As a confirmation of this hypothesis, the DIGAMI study (Diabetes Mellitus, Insulin Glucose Infusion in Acute Myocardial Infarction) showed that GIKi administration in the early 24 hours after acute myocardial infarction (AMI), followed by a multidose subcutaneous insulin regimen, facilitates a persistent improvement of glucose control and reduces the long-term mortality in diabetic patients. The gene discussed is INS; the disease is acute myocardial infarction.